About AFT Pharmaceuticals

AFT Pharmaceuticals is a 100% privately owned pharmaceutical company operating in Australia and New Zealand with full development, regulatory and sales/marketing operations.

In addition to distributing agency lines, AFT owns a significant portfolio of IP (trademarks, patents) and product licenses. AFT markets patented, branded & generic drugs and is also involved in drug development.

1998 – started in NZ with first sales made

2000 – acquired shareholdings in 2 South African Pharmaceutical Companies and a wholesaler

2002 – acquired first AFT wholly owned products

2004 – started Australian company and exited South Africa Investment

2004 – started drug development work and filed first 2 global patents

2005 - started first Australian sales

2006 – JV drug development agreement with an EU based company

2008 – Secured an  outlicensing deal for 3 AFT products in SE Asia. Dec08, first launches in Malaysia

2009 – Global licensing negotiations for key development project

2009 – Launch of world first combination analgesic - Maxigesic – into New Zealand

2012 - R&D spend increased to $4 million per annum

2012 - Distribution and outlicensing agreements expanded to include 42 countries

2012 - Group Sales to exceeded $50 million per annum

2012 - Started AFT Pharmaceuticals in Singapore and Malaysia, Started AFT Orphan

2013 - Regulatory filings in over 30 countries around the world

Our objective is to build a significant Australasian Pharmaceutical company which is also involved in drug development.